Pharmacology Mnemonics - Flash Cards

Name: Abciximab (Reo-Pro)

Class: Antithrombotic Agent (Antiplatelet Agent)

Mechanism: Monoclonal antibody to GPIIb/IIIa. Interferes w/platelet-adhesive protein interactions.

Absorption:

Dist.:

Metabolism.:

Excretion, t½:

Toxicity/S.E.s:

Utility: Treat high risk angioplasty pts.

Special Features:

Name: Ticlopidine (Ticlid)

Class: Antithrombotic Agent (Antiplatelet Agent)

Mechanism: Unknown. Through some effect on platelet membranes, blocks ADP-induced aggregation. Interacts w/membrane glycoprotein IIb/IIIa.

Absorption:

Dist.:

Metabolism.:

Excretion, t½:

Toxicity/S.E.s: Diarrhea, GI cramping, rash, ­ LDL & VLDL, leukopenia, agranulocytosis, pancytopenia.

Utility: Treat thromboses in patients unable to take aspirin. May be more effective than aspirin in 2° prevention of stroke in pts w/previous TIA.

Special Features: Several days required for effects to develop. Effects persist for several days after cessation of treatment. As effective in E as in G. Antithrombotic use is primarily for arterial thromboses.

Name: Dipyridamole (Persantine)

Class: Antithrombotic Agent (Antiplatelet Agent)

Mechanism: Inhib. PDE in platelets ® ­ cAMP ® inhib. of platelet activation.

Absorption:

Dist.:

Metabolism.:

Excretion, t½:

Toxicity/S.E.s:

Utility: Prevention of systemic embolism in pts. w/prosthetic heart valves. Admin. in combination w/warfarin.

Special Features: When used alone, ineffective for Rx of cerebral or CV thrombotic events. Not proven to be of additional benefit when admin. w/aspirin. Antithrombotic use is primarily for arterial thromboses.

Name: Acetylsalicylic Acid (Aspirin)

Class: Antithrombotic Agent (Antiplatelet Agent)

Mechanism: Irrevers. acetylation of cyclooxygenase ® ¯ platelet thromboxane synth.

Absorption: Oral ® rapid absorption.

Dist.:

Metabolism.:

Excretion, t½:

Toxicity/S.E.s: GI hemorrhage, hemorrhagic stroke. Use w/caution in pts on long-term oral anticoagulants. Hypersensitivity rxns—generalized urticaria, bronchial asthma, laryngeal edema, bronchoconstriction, hypotension, shock—may occur in 20-25% of pts w/asthma, nasal polyps, or chronic urticaria.

Utility: Acute MI, stable/unstable angina, 2° prevention in MI survivors. TIA. 2° prevention in nondisabling ischemic stroke. Prevention of saphenous vein bypass graft occlusion. Post-coronary angioplasty. 1° MI prophylaxis (325 mg/d) adjunctive to risk factor management. Headache.

Special Features: Low dose Rx optimal—75-325 mg/d. Antithrombotic use is primarily for arterial thromboses.